Ichnos Glenmark Innovation (IGI) has announced promising initial results from its Phase 1 trial of ISB 2001, a trispecific antibody targeting relapsed/refractory multiple myeloma (r/rMM). At the upcoming 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, IGI will present detailed findings from this study.
Key Highlights:
- ISB 2001 Safety and Efficacy: ISB 2001 demonstrated a favorable safety profile and achieved an overall response rate (ORR) of 75% in patients with r/rMM, showing promising results as a new treatment option for this condition.
- Additional Study: IGI will also present safety and tolerability data from the Phase 1/2 study of ISB 1442, another investigational therapy for r/rMM.
Presentation Schedule:
- ISB 2001 Oral Presentation: Hang Quach, M.B.B.S, will present findings on December 9, 2024, at the San Diego Convention Center, Hall B.
- ISB 1442 Poster Presentation: Binod Dhakal, M.D., will present data on December 8, 2024, at the San Diego Convention Center, Halls G-H.
These presentations will explore the potential of ISB 2001 and ISB 1442 to address the challenges in treating multiple myeloma, focusing on their response rates, safety, and tolerability.
TOPICS:
Glenmark